K-numberK242123
Device nameBrainomix 360 e-CTA
ApplicantBrainomix Limited
Product codeLLZ
Device classClass II
Decision dateJan 6, 2025
DecisionSubstantially Equivalent
Regulation892.2050
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

Brainomix 360 e-CTA is medical image processing software for visualizing, analyzing, and post-processing CT angiography (CTA) images. It runs on standard off-the-shelf hardware and processes DICOM-compliant images, allowing trained professionals such as physicians and medical technicians to perform image viewing and analysis to support clinical decision-making. The software is not intended for mobile diagnostic use.

Technological characteristics

The proposed device introduces three new features compared to the primary predicate: (1) an AI/ML algorithm to distinguish bone from vessels and reduce image grain, improving vessel detection; (2) accessible posterior MIP views for focused visualization of posterior large vessels; and (3) a 3D-colored transparency overlay to visualize MCA hemisphere vessel density asymmetry. These features are similar to the secondary predicate's technological approach but differ in presentation (e.g., transparency scale versus multi-colored scale).

Test standards cited

ISO 14971:2019 (risk management), FDA Cybersecurity Guidance, and IEC 81001-5-1 (cybersecurity). The device was designed and verified in compliance with 21 CFR Part 820.30 (design controls).

Substantial equivalence argument

The proposed device has identical intended use to the primary predicate (CTA image processing) and performs the same basic functions. Although it introduces an AI/ML algorithm and new visualization features, digital phantom testing demonstrates the algorithm reduces mean absolute error without raising new safety or effectiveness questions, and the added views and overlay are visualization enhancements that do not alter clinical workflow. The secondary predicate (Rapid) similarly uses AI/ML and colored overlays for vessel density analysis, establishing that these technological improvements are established in the market and do not require new performance evidence beyond the comparison study of 308 clinical CTA scans, which showed consistent performance across patient subgroups, scanner manufacturers, and clinical sites.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →